VinpotropilВинпотропил
A fixed-dose combination of piracetam and vinpocetine investigated in cerebrovascular and cognitive research.
What the studies found
Observational study · 2010
MMSE rose 1.9 points in the 13-person stage II subgroup
- Mean MMSE change in stage II subgroup
- +1.9 points (n=13)Baseline 26.2 ± 2.4, day 30 28.2 ± 2.4. The published change is 1.9 points.Day 30
- Patients rating response good or very good
- 15/20 (75%)Day 30
- Objective neurological deficit
- Unchanged.
Mean MMSE rose by a reported 1.9 points in the 13 patients with stage II disease. Fifteen of 20 participants rated the response good or very good. Objective neurological deficit was unchanged.
More reported outcomes
- Reported adverse effects
- None in the 20 patients during 30 days.
Study notes · methods, sources and limitations
Participants or model 20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.
Design Open single-cohort study, n=20. All 20 completed treatment and cognitive testing. Seven had stage I and 13 had stage II disease.
Important limitations
- Repeated cognitive testing and background care may influence the change. The two publication versions describe the same patients. The study addressed chronic cerebral ischemia.
- The 2012 republication credits the 2010 original (DOI 10.61788/njn.v1i12.14). A comparator is needed to estimate a treatment effect.
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(9):39–42. Reprinted in National Journal of Neurology (2012). · Publication record
Observational study · 2010
Vinpotropil in chronic cerebrovascular cognitive impairment
- Executive function and neurological symptoms
- Improvement on repeat testing and symptom ratings was reported.Three months
The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.
Study notes · methods, sources and limitations
Participants or model 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
Design Multicenter before-and-after report in 349 patients given oral vinpocetine plus piracetam for three months.
Important limitations
- The indexed abstract describes a treated cohort. It gives no independent comparator, effect sizes, arm counts or numerical adverse-event rates.
- The abstract does not report comparative effect sizes or adverse-event counts.
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 1):13–16. · Indexed abstract
Study involving people · 2007
Vinpotropil during early ischemic stroke rehabilitation
- Tolerability and convenience
- Favorable patient reports for the fixed combination.No numerical neurological or functional outcome in the abstract.
Patients reported that the fixed combination was well tolerated and more convenient to take than separate tablets. The abstract does not quantify a stroke recovery outcome.
Study notes · methods, sources and limitations
Participants or model Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.
Important limitations
- The original tables are needed for group sizes, drug regimen and neurological or functional outcomes. The chronic cerebral ischemia reports involve a different clinical setting.
- The original report is needed for enrollment, intervention schedules, and outcomes by arm.
Zh Nevrol Psikhiatr Im S S Korsakova. 2007;Suppl 21:52–56. · Indexed abstract
About Vinpotropil
Identity / background source ↗
Research background
Fixed vinpocetine–piracetam preparation studied in chronic cerebral ischemia and early stroke rehabilitation. Separate environmental and military comparisons are also indexed.
More study findings
Randomized study in people · 2008
Cortexin and other adjuncts in military combined-injury rehabilitation
Study of multiple preparations
- Cortexin · work-capacity score
- 516.0±21.4 → 569.3±5.2Day 1 to day 14. Standard care 526.1±10.2 → 509.8±12.2.Reported p<0.05 versus standard care
- Vinpotropil · work-capacity score
- 524.1±23.7 → 613.2±19.5Day 1 to day 14. Separate treatment arm.Reported p<0.05 versus standard care
- Cortexin · clinician-rated anxiety
- 13.4±2.1 → 4.5±0.6Day 14. All arms showed some improvement.
Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.
More reported outcomes
- Attrition
- 16 early discharges; zero attributed to adverse effectsThe abstract does not provide a comprehensive adverse-event table.
Study notes · methods, sources and limitations
Participants or model 317 screened, 76 selected (61 men and 15 women), 60 analyzed in four groups of 15. Sixteen early discharges.
Design Author-described double-blind randomized adjunctive study. Outcomes at days 7 and 14 included asthenia, anxiety, memory and tapping-based performance. Control included B-vitamin injections.
- Reported study exposure
- Cortexin 10 mg intramuscularly once daily, Mexidol 100 mg intramuscularly once daily, or Vinpotropil one oral capsule three times daily as separate adjuncts. Standard-care comparator included B1 and B6 injections.
Important limitations
- Blinding implementation across different routes is unclear. Complete arm flow, attrition by arm and outcome units need the full dissertation.
- This is short-term treatment research in hospitalized patients after trauma. The 60 analyzed are included within the 76 selected.
Kirov Military Medical Academy candidate dissertation author abstract · Kirov Military Medical Academy candidate dissertation author abstract
Comparison in people · 2007
Meteoadaptogenic properties of nootrop drugs
Study of multiple preparations
- Noopept
- Favorable psychological measures in heat and cold; physical efficiency reported in heatNo effect sizes in the publisher abstract.
- Cortexin and Vinpotropil
- Cortexin effects described in cold and hypoxia; Vinpotropil in cold and heatDistinct preparations and endpoints.
- Dilept
- Favorable psychological functional-state measures describedNo numerical comparison or group counts in the abstract.
The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.
Study notes · methods, sources and limitations
Participants or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
Design Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.
Important limitations
- The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open. This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review. Possible cohort overlap with the 2007 paper; not independent replication.
- Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.
Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted · Bibliographic lead
Performance research in context
- Compound class
- Environmental nootropic research
- Research collection
- Related nootropics & combinations · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
A 349-person multicenter report and a 20-person open study, plus a stroke rehabilitation report
Study methods
The chronic ischemia studies report outcomes during treatment. The stroke abstract gives no arm-level results.
Independent replication
Possible overlap with the Academy report
Source access
Journal abstracts and a republication of the 20-person study
Safety evidence
Original adverse-event tables are incomplete
Open a topic for the evidence assessment.
Patents and claimed inventions
These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.
Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →
Findings by study
Observational study · 2010
Vinpotropil in chronic cerebrovascular cognitive impairment
The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.
Study notes and original source
Vinpotropil in chronic cerebrovascular cognitive impairment
V. V. Zakharov · Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(11 Pt 1):13–16.
The multicenter report describes improvement on repeat executive-function testing and in several self-reported symptoms after three months.
Results and tables
Reported findings and study design
Findings described in words
Multicenter before-and-after report in 349 patients given oral vinpocetine plus piracetam for three months.
Population or model 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
Dose, route and schedule
One capsule containing 5 mg vinpocetine and 400 mg piracetam, three times daily for three months.
Protocol source ↗ · Indexed English abstract of the original Russian journal report.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Executive function and neurological symptoms | Improvement on repeat testing and symptom ratings was reported. | Three months |
The abstract does not report comparative effect sizes or adverse-event counts.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 349 patients with stage I–II dyscirculatory encephalopathy and cognitive impairment without dementia.
- Source reviewed
- Indexed English abstract of the original Russian journal report.
Study limitations
- The indexed abstract describes a treated cohort. It gives no independent comparator, effect sizes, arm counts or numerical adverse-event rates.
Reviewed 2026-11-14.
Observational study · 2010
Vinpotropil in early chronic cerebral ischemia: open study
Mean MMSE rose by a reported 1.9 points in the 13 patients with stage II disease. Fifteen of 20 participants rated the response good or very good. Objective neurological deficit was unchanged.
Study notes and original source
Vinpotropil in early chronic cerebral ischemia: open study
O. V. Vorob’eva, E. S. Tamarova · Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(9):39–42. Reprinted in National Journal of Neurology (2012).
Mean MMSE rose by a reported 1.9 points in the 13 patients with stage II disease. Fifteen of 20 participants rated the response good or very good. Objective neurological deficit was unchanged.
Results and tables
Reported findings and study design
Open single-cohort study, n=20. All 20 completed treatment and cognitive testing. Seven had stage I and 13 had stage II disease.
Population or model 20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.
Dose, route and schedule
Two capsules orally three times daily before meals for 30 days alongside existing care. Each capsule contained 5 mg vinpocetine and 400 mg piracetam.
Protocol source ↗ · Indexed original abstract and the credited 2012 journal republication.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mean MMSE change in stage II subgroup | +1.9 points (n=13) | Baseline 26.2 ± 2.4, day 30 28.2 ± 2.4. The published change is 1.9 points. · Day 30 |
| Patients rating response good or very good | 15/20 (75%) | Day 30 |
| Objective neurological deficit | Unchanged. | |
| Reported adverse effects | None in the 20 patients during 30 days. |
The 2012 republication credits the 2010 original (DOI 10.61788/njn.v1i12.14). A comparator is needed to estimate a treatment effect.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- 20 patients aged 50–78. Seven with stage I and thirteen with stage II disease. Single treated cohort.
- Source reviewed
- Indexed original abstract and the credited 2012 journal republication.
Study limitations
- Repeated cognitive testing and background care may influence the change. The two publication versions describe the same patients. The study addressed chronic cerebral ischemia.
Reviewed 2026-11-14.
Study involving people · 2007
Vinpotropil during early ischemic stroke rehabilitation
Patients reported that the fixed combination was well tolerated and more convenient to take than separate tablets. The abstract does not quantify a stroke recovery outcome.
Study notes and original source
Vinpotropil during early ischemic stroke rehabilitation
A. N. Kuznetsov, V. D. Daminov · Zh Nevrol Psikhiatr Im S S Korsakova. 2007;Suppl 21:52–56.
Patients reported that the fixed combination was well tolerated and more convenient to take than separate tablets. The abstract does not quantify a stroke recovery outcome.
Results and tables
Reported findings and study design
Findings described in words
Population or model Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Tolerability and convenience | Favorable patient reports for the fixed combination. | No numerical neurological or functional outcome in the abstract. |
The original report is needed for enrollment, intervention schedules, and outcomes by arm.
Source for these results ↗ · Reviewed 2026-11-14
- Population / setting
- Patients in early ischemic stroke rehabilitation. Enrollment and arm sizes are absent from the abstract.
- Source reviewed
- Indexed English abstract of the original Russian journal report.
Study limitations
- The original tables are needed for group sizes, drug regimen and neurological or functional outcomes.
- The chronic cerebral ischemia reports involve a different clinical setting.
Reviewed 2026-11-14.
Randomized study in people · 2008
Cortexin and other adjuncts in military combined-injury rehabilitation
Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.
Study notes and original source
Cortexin and other adjuncts in military combined-injury rehabilitation
· Kirov Military Medical Academy candidate dissertation author abstract
Format: Author’s abstract transcription. Full dissertation and underlying records unavailable. · Reviewed: Reported methods, results and evidence limitations
I. Yu. Khabarov · Kirov Military Medical Academy candidate dissertation author abstract
Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.
Results and tables
Reported findings and study design
Reported work-capacity scores rose from 516.0 to 569.3 with Cortexin and from 524.1 to 613.2 with Vinpotropil. Standard care fell from 526.1 to 509.8.
Author-described double-blind randomized adjunctive study. Outcomes at days 7 and 14 included asthenia, anxiety, memory and tapping-based performance. Control included B-vitamin injections.
Population or model 317 screened, 76 selected (61 men and 15 women), 60 analyzed in four groups of 15. Sixteen early discharges.
Dose, route and schedule
Cortexin 10 mg intramuscularly once daily, Mexidol 100 mg intramuscularly once daily, or Vinpotropil one oral capsule three times daily as separate adjuncts. Standard-care comparator included B1 and B6 injections.
Protocol source ↗ · Author’s abstract transcription. Full dissertation and underlying records unavailable.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Cortexin · work-capacity score | 516.0±21.4 → 569.3±5.2 | Day 1 to day 14. Standard care 526.1±10.2 → 509.8±12.2. · Reported p<0.05 versus standard care |
| Vinpotropil · work-capacity score | 524.1±23.7 → 613.2±19.5 | Day 1 to day 14. Separate treatment arm. · Reported p<0.05 versus standard care |
| Cortexin · clinician-rated anxiety | 13.4±2.1 → 4.5±0.6 | Day 14. All arms showed some improvement. |
| Attrition | 16 early discharges; zero attributed to adverse effects | The abstract does not provide a comprehensive adverse-event table. |
This is short-term treatment research in hospitalized patients after trauma. The 60 analyzed are included within the 76 selected.
Source for these results ↗ · Reviewed 2026-11-09
- Population / setting
- 317 screened, 76 selected (61 men and 15 women), 60 analyzed in four groups of 15. Sixteen early discharges.
- Source reviewed
- Author’s abstract transcription. Full dissertation and underlying records unavailable.
Study limitations
- Blinding implementation across different routes is unclear. Complete arm flow, attrition by arm and outcome units need the full dissertation.
Reviewed 2026-11-09.
Experiment described in a patent · 2008
Vinpotropil: vinpocetine plus piracetam — EA009666B1
The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.
Study notes and original source
Vinpotropil: vinpocetine plus piracetam — EA009666B1
Patent-defined substance or composition · Patent publication
Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
· EA009666B1 · patent family 34545985
The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.
Results and tables
Reported patent results
Reported findings
The patent reports improvement in anxiety and selected attention/symptom measures, with neutral depression comparisons.
Early post-ischemic-stroke comparison of fixed-combination Vinpotropil with vinpocetine, piracetam and separately combined ingredients; assessments at baseline and day 21.
Population or model Early post-ischemic-stroke comparison of fixed-combination Vinpotropil with vinpocetine, piracetam and separately combined ingredients; assessments at baseline and day 21.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anxiety score | Vinpotropil 32.7 → 17.6; other displayed groups 30.1 → 26.5, 30.0 → 22.3 and 31.5 → 24.7 | Spielberger score; before/after significance is not a verified between-group treatment effect · 21 days |
| Depression score | Vinpotropil 21.1 → 20.2; no significant differences reported in any group | Neutral depression result retained · 21 days |
| Withdrawals and gastric symptoms | 2 main-group and 6 comparator-group exclusions; gastric/dyspeptic complaints reported in 5% fixed-combination versus 20% separate-combination group | Group denominators and analysis of withdrawals need original-trial verification |
Unclear allocation, co-treatment and incomplete group reporting prevent proof of synergy or superiority of the fixed formulation. These patent observations may overlap the clinical literature.
Source for these results ↗ · Reviewed 2026-11-06
- Population / setting
- Early post-ischemic-stroke comparison of fixed-combination Vinpotropil with vinpocetine, piracetam and separately combined ingredients; assessments at baseline and day 21.
- Source reviewed
- Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
- A fixed-combination claim does not establish either ingredient's independent effect or demonstrate pharmacological synergy.
- Unclear allocation, co-treatment and incomplete group reporting prevent proof of synergy or superiority of the fixed formulation. These patent observations may overlap the clinical literature.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Reviewed 2026-11-06.
Controlled study in people · 2007
Meteoadaptogenic properties of peptide drugs in healthy volunteers
A program involving 127 healthy men compared four preparations under cold, heat and simulated altitude. Results varied by compound and test.
Study notes and original source
Meteoadaptogenic properties of peptide drugs in healthy volunteers
Format: Original journal PDF · Reviewed: Original publisher PDF, printed pages 42–44: legacy Cyrillic text decoded and selected results rows checked; visual table appraisal remains open
P. D. Shabanov, V. P. Ganapolsky, P. V. Aleksandrov · Eksp Klin Farmakol. 70(6):41–47
Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.
Results and tables
Reported findings and study design
Noopept showed different performance and anxiety results under cold, heat and simulated altitude. The tables also distinguish Cortexin, Dilept and Vinpotropil.
127 healthy men across the program; active subgroups 10–20 and placebo 8–10 per stage. Program size is not the number given Noopept. Cold −10°C, heat +45°C and simulated altitude 3,000 m.
Population or model 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Noopept PWC170 in cold | 189 ± 10 versus 162 ± 2 | Placebo comparison in the cold chamber; source PWC170 values, units not added · Cold chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept PWC170 in heat | 188 ± 6 versus 152 ± 1 | Placebo in the heat chamber; values checked in Table 2 · Heat chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept arithmetic errors in heat | 0 ± 0 versus 0.8 ± 0.2 | Placebo in the heat chamber; test-specific errors · Heat chamber · Source significance marker versus placebo and historical control |
| Noopept state / trait anxiety in heat | 27 ± 3 / 27 ± 2 | Historical controls: 38 ± 2 / 34 ± 3; retain separate comparison identities · Heat chamber · Source marks p<0.05 versus placebo and historical control |
| Noopept PWC170 at simulated altitude | 197 ± 8 versus 154 ± 3 | Concurrent placebo; source values · Simulated 3,000 m · Source marks p<0.05 versus placebo and historical control |
| Noopept activity self-rating in heat | 5.9 ± 0.4 versus 4.2 ± 0.2 | Historical no-drug controls; the placebo value is separately shown in the table · Heat chamber |
Cold chamber (−10°C): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 46 ± 5 | 153 ± 7 | 1.5 ± 0.01 | 10.5 ± 1.2 | 1.2 ± 0.8 | 33 ± 3 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 42 ± 1b | 155 ± 1b | 1.5 ± 0.001 | 9.3 ± 1.7 | 1.5 ± 0.6 | 33 ± 3 | 31 ± 4 | 5.6 ± 0.4 | 5.3 ± 0.3 | 5.7 ± 0.5 |
| Before chamber | Vinpotropil | 44 ± 3 | 219 ± 9ab | 1.6 ± 0.01ab | 10.5 ± 1.0 | 2.1 ± 0.9 | 35 ± 3 | 32 ± 3 | 5.1 ± 0.3 | 5.0 ± 0.2 | 4.8 ± 0.5 |
| Before chamber | Noopept | 46 ± 3 | 189 ± 3ab | 1.6 ± 0.01ab | 9.2 ± 1.2 | 0.4 ± 0.2 | 28 ± 2a | 27 ± 2 | 6.0 ± 0.9 | 6.3 ± 0.8 | 6.2 ± 0.7 |
| Before chamber | Dilept | 42 ± 1b | 176 ± 1ab | 1.5 ± 0.02 | 10.8 ± 1.8 | 0.8 ± 0.4 | 28 ± 2a | 28 ± 3 | 6.2 ± 0.7 | 5.4 ± 0.7 | 5.8 ± 0.3 |
| Before chamber | Placebo | 48 ± 2 | 159 ± 3 | 1.5 ± 0.01 | 9.7 ± 0.7 | 1.2 ± 0.6 | 31 ± 4 | 31 ± 3 | 5.6 ± 0.2 | 5.2 ± 0.3 | 5.6 ± 0.4 |
| In chamber | Historical no-drug control | 45 ± 5 | 165 ± 7 | 1.5 ± 0.01 | 9.8 ± 1.9 | 2.5 ± 0.4 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 45 ± 3 | 210 ± 7ab | 1.6 ± 0.02ab | 11.0 ± 1.9 | 0.3 ± 0.3ab | 38 ± 4 | 31 ± 4 | 5.2 ± 0.3 | 4.7 ± 0.4 | 5.1 ± 0.4 |
| In chamber | Vinpotropil | 45 ± 2 | 219 ± 13ab | 1.6 ± 0.02ab | 7.5 ± 0.8b | 0.5 ± 0.2ab | 36 ± 2 | 28 ± 3a | 4.9 ± 0.3b | 4.9 ± 0.1 | 5.1 ± 0.3 |
| In chamber | Noopept | 44 ± 2 | 189 ± 10ab | 1.6 ± 0.02ab | 10.6 ± 1.5 | 1.6 ± 0.6 | 30 ± 3a | 27 ± 3a | 5.3 ± 0.3 | 6.0 ± 1.1a | 6.4 ± 0.8 |
| In chamber | Dilept | 41 ± 1ab | 182 ± 5ab | 1.7 ± 0.01ab | 10.8 ± 1.9 | 0.8 ± 0.4a | 29 ± 3a | 28 ± 3a | 5.9 ± 0.5a | 5.3 ± 0.3a | 5.4 ± 0.6 |
| In chamber | Placebo | 47 ± 2 | 162 ± 2 | 1.5 ± 0.01 | 10.0 ± 0.6 | 1.2 ± 0.5 | 33 ± 3 | 32 ± 3 | 5.4 ± 0.2 | 5.1 ± 0.4 | 5.5 ± 0.3 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Heat chamber (+45°C): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 47 ± 3 | 161 ± 4 | 1.5 ± 0.01 | 10.5 ± 1.0 | 1.2 ± 0.8 | 33 ± 2 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 43 ± 2 | 181 ± 5ab | 1.6 ± 0.01ab | 11.5 ± 1.6 | 0.67 ± 0.2 | 35 ± 3 | 32 ± 3 | 5.1 ± 0.3 | 4.9 ± 0.2 | 4.8 ± 0.5 |
| Before chamber | Vinpotropil | 45 ± 2 | 189 ± 9ab | 1.6 ± 0.02ab | 10.7 ± 1.0 | 0.9 ± 0.4 | 29 ± 3 | 26 ± 3 | 5.9 ± 0.3 | 5.8 ± 0.2ab | 5.9 ± 0.3 |
| Before chamber | Noopept | 48 ± 3 | 182 ± 3ab | 1.6 ± 0.01ab | 9.6 ± 1.3 | 0.8 ± 0.4 | 28 ± 3a | 27 ± 3 | 6.1 ± 0.2a | 6.1 ± 0.3ab | 6.4 ± 0.3ab |
| Before chamber | Dilept | 44 ± 2 | 180 ± 7ab | 1.6 ± 0.01ab | 9.7 ± 1.8 | 0.7 ± 0.2 | 26 ± 3ab | 28 ± 3 | 5.4 ± 0.2 | 4.6 ± 0.5b | 4.9 ± 0.2 |
| Before chamber | Placebo | 46 ± 2 | 164 ± 2 | 1.5 ± 0.01 | 11.0 ± 0.6 | 1.0 ± 0.1 | 32 ± 3 | 30 ± 3 | 5.5 ± 0.2 | 5.3 ± 0.2 | 5.5 ± 0.5 |
| In chamber | Historical no-drug control | 47 ± 4 | 151 ± 5 | 1.5 ± 0.01 | 9.8 ± 1.9 | 2.5 ± 0.4 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 39 ± 1a | 155 ± 9 | 1.5 ± 0.02 | 9.6 ± 1.1 | 0.8 ± 0.7a | 36 ± 2 | 28 ± 3a | 4.9 ± 0.3 | 4.9 ± 0.1a | 5.1 ± 0.3 |
| In chamber | Vinpotropil | 41 ± 2a | 202 ± 11ab | 1.6 ± 0.02ab | 10.3 ± 1.1 | 0.7 ± 0.4a | 31 ± 3 | 27 ± 3ab | 5.7 ± 0.2ab | 5.6 ± 0.2ab | 5.9 ± 0.3b |
| In chamber | Noopept | 44 ± 3 | 188 ± 6ab | 1.6 ± 0.01ab | 12.0 ± 1.4 | 0 ± 0ab | 27 ± 3ab | 27 ± 2ab | 6.2 ± 0.3ab | 5.9 ± 0.4ab | 6.2 ± 0.2ab |
| In chamber | Dilept | 42 ± 2 | 174 ± 9ab | 1.5 ± 0.01ab | 10.5 ± 0.9 | 0.8 ± 0.5a | 27 ± 3ab | 28 ± 2ab | 5.1 ± 0.3 | 4.6 ± 0.2a | 4.9 ± 0.2 |
| In chamber | Placebo | 42 ± 4 | 152 ± 1 | 1.5 ± 0.01 | 10.9 ± 1.3 | 0.8 ± 0.2 | 34 ± 3 | 33 ± 3 | 5.3 ± 0.2 | 4.9 ± 0.3 | 5.3 ± 0.2 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Simulated altitude (3,000 m): selected reported rows
| Setting | Preparation | Grip strength, kg | PWC170 | Max oxygen uptake, L | Arithmetic actions | Arithmetic errors | State anxiety | Trait anxiety | Well-being | Activity | Mood |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Before chamber | Historical no-drug control | 46 ± 5 | 151 ± 4 | 1.3 ± 0.01 | 10.5 ± 1.0 | 1.2 ± 0.8 | 33 ± 2 | 31 ± 4 | 5.6 ± 0.3 | 4.9 ± 0.2 | 5.5 ± 0.5 |
| Before chamber | Cortexin | 42 ± 2 | 170 ± 5a | 1.6 ± 0.01ab | 9.7 ± 0.6 | 0.2 ± 0.12 | 34 ± 3 | 32 ± 3 | 5.6 ± 0.3 | 5.1 ± 0.2 | 5.5 ± 0.3 |
| Before chamber | Vinpotropil | 46 ± 2 | 195 ± 5ab | 1.6 ± 0.01ab | 9.0 ± 0.5 | 0.5 ± 0.2 | 28 ± 3 | 27 ± 3 | 6.1 ± 0.2ab | 6.1 ± 0.3ab | 6.4 ± 0.3ab |
| Before chamber | Noopept | 47 ± 3 | 202 ± 3ab | 1.6 ± 0.01ab | 11.2 ± 0.6 | 0.2 ± 0.2 | 29 ± 3 | 26 ± 2 | 5.9 ± 0.3 | 5.8 ± 0.2a | 5.9 ± 0.3 |
| Before chamber | Dilept | 41 ± 1 | 181 ± 3ab | 1.6 ± 0.01ab | 14.2 ± 3.0 | 1.0 ± 0.6 | 27 ± 3a | 28 ± 2 | 6.2 ± 0.2ab | 5.8 ± 0.1a | 5.8 ± 0.2 |
| Before chamber | Placebo | 46 ± 4 | 162 ± 5 | 1.5 ± 0.01 | 10.1 ± 0.8 | 0.6 ± 0.1 | 33 ± 3 | 30 ± 3 | 5.5 ± 0.2 | 5.6 ± 0.2 | 5.6 ± 0.4 |
| In chamber | Historical no-drug control | 46 ± 4 | 145 ± 5 | 1.3 ± 0.01 | 9.8 ± 1.9 | 3 ± 0.6 | 38 ± 2 | 34 ± 3 | 5.0 ± 0.1 | 4.2 ± 0.2 | 5.4 ± 0.4 |
| In chamber | Cortexin | 41 ± 2 | 170 ± 6ab | 1.6 ± 0.01ab | 9.7 ± 0.6 | 0.2 ± 0.2a | 34 ± 3 | 32 ± 3 | 5.4 ± 0.2 | 5.0 ± 0.2ab | 5.4 ± 0.2 |
| In chamber | Vinpotropil | 44 ± 2 | 196 ± 6ab | 1.6 ± 0.01ab | 10.4 ± 0.9 | 0.8 ± 0.3a | 27 ± 3ab | 27 ± 2ab | 6.2 ± 0.3ab | 5.9 ± 0.4ab | 6.2 ± 0.2ab |
| In chamber | Noopept | 45 ± 3 | 197 ± 8ab | 1.6 ± 0.01ab | 11.4 ± 1.7 | 2.2 ± 2.2 | 31 ± 4a | 27 ± 3ab | 5.7 ± 0.2a | 5.6 ± 0.2ab | 5.9 ± 0.3 |
| In chamber | Dilept | 41 ± 1 | 186 ± 6ab | 1.6 ± 0.01ab | 12.6 ± 2.5 | 0.6 ± 0.4a | 28 ± 3a | 28 ± 3ab | 6.3 ± 0.2ab | 5.6 ± 0.3ab | 6.1 ± 0.3ab |
| In chamber | Placebo | 46 ± 4 | 154 ± 3 | 1.5 ± 0.01 | 9.5 ± 1.0 | 0.6 ± 0.2 | 33 ± 3 | 34 ± 3 | 5.4 ± 0.3 | 4.6 ± 0.1 | 5.6 ± 0.2 |
Reported central values with source uncertainty terms. a: p<0.05 versus no-drug control; b: p<0.05 versus placebo. Groups already differed before chamber entry. Historical controls are not concurrent randomized controls. Legacy text decoding was checked; full visual appraisal remains open.
Pre-chamber group differences, historical controls and unclear allocation limit attribution. The preparation-specific rows cannot be applied interchangeably to all four compounds. Experimental formulations and short chamber tasks do not establish safe performance during dangerous work.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 127 healthy men aged 20–24 across a three-day environmental program; active groups reported as 10–20, placebo 8–10 per stage
- Source reviewed
- Previously reviewed original journal PDF methods and selected tables. The separately recovered 86-man proceedings abstract is related; participant overlap remains unresolved.
Study limitations
- Random allocation and blinding not established; historical controls and baseline differences limit attribution.
- Exact arm-by-environment denominators remain unresolved; 127 is the program total, not Noopept enrollment.
- Experimental intranasal peptide preparations are not equivalent to marketed oral products.
- No validated protection from heat illness, operational accidents or long-term harm.
- The Academy report may cover the same participants.
Reviewed 2026-11-08.
Comparison in people · 2007
Meteoadaptogenic properties of nootrop drugs
The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.
Study notes and original source
Meteoadaptogenic properties of nootrop drugs
V. P. Ganapolsky, A. A. Elistratov, P. V. Alexandrov, P. D. Shabanov, E. G. Mokeeva, E. A. Mitin, V. I. Kruglov · Bulletin of the Russian Military Medical Academy. No. 4:61–66; date discrepancy noted
The Academy abstract describes stressor-specific functional-state findings across four compounds, including Noopept. It emphasizes mental work capacity and heat/high-altitude adaptation.
Results and tables
Reported findings and study design
Qualitative, stressor-specific comparisons.
Academy report on cold, heat and hypobaric hypoxia, with cohort overlap unresolved.
Population or model Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Noopept | Favorable psychological measures in heat and cold; physical efficiency reported in heat | No effect sizes in the publisher abstract. |
| Cortexin and Vinpotropil | Cortexin effects described in cold and hypoxia; Vinpotropil in cold and heat | Distinct preparations and endpoints. |
| Dilept | Favorable psychological functional-state measures described | No numerical comparison or group counts in the abstract. |
Related to the 86-man and 127-man reports. Avoid pooling or importing their doses and estimates.
Source for these results ↗ · Reviewed 2026-11-08
- Population / setting
- Healthy men aged 20–24; −10°C, +45°C and hypoxia (reported pO₂ 109.9 mmHg)
- Source reviewed
- Publisher metadata and Russian abstract checked. A related manufacturer-hosted PDF is indexed, but direct download timed out; the PDF contents were not appraised.
Study limitations
- The current publisher record says 2007, issue 4, pp. 61–66; later bibliographies cite 2008. Original issue verification remains open.
- This abstract differs from the Eksp Klin Farmakol summary, including the Cortexin/cold account. Differences are preserved pending table-level review.
- Possible cohort overlap with the 2007 paper; not independent replication.
Reviewed 2026-09-29.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗